GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (LTS:0A4Y) » Definitions » Gross Profit

AIM ImmunoTech (LTS:0A4Y) Gross Profit : $0.14 Mil (TTM As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is AIM ImmunoTech Gross Profit?

AIM ImmunoTech's gross profit for the three months ended in Dec. 2024 was $0.04 Mil. AIM ImmunoTech's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $0.14 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. AIM ImmunoTech's gross profit for the three months ended in Dec. 2024 was $0.04 Mil. AIM ImmunoTech's Revenue for the three months ended in Dec. 2024 was $0.05 Mil. Therefore, AIM ImmunoTech's Gross Margin % for the quarter that ended in Dec. 2024 was 84.44%.

AIM ImmunoTech had a gross margin of 84.44% for the quarter that ended in Dec. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of AIM ImmunoTech was 81.77%. The lowest was -1104.35%. And the median was -394.48%.


AIM ImmunoTech Gross Profit Historical Data

The historical data trend for AIM ImmunoTech's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Gross Profit Chart

AIM ImmunoTech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.64 -0.72 0.14 0.16 0.14

AIM ImmunoTech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.03 0.04 0.03 0.04

Competitive Comparison of AIM ImmunoTech's Gross Profit

For the Biotechnology subindustry, AIM ImmunoTech's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Gross Profit distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Gross Profit falls into.


;
;

AIM ImmunoTech Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

AIM ImmunoTech's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=0.17 - 0.031
=0.14

AIM ImmunoTech's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=0.045 - 0.007
=0.04

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.14 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

AIM ImmunoTech's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.04 / 0.045
=84.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


AIM ImmunoTech  (LTS:0A4Y) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

AIM ImmunoTech had a gross margin of 84.44% for the quarter that ended in Dec. 2024 => Durable competitive advantage


AIM ImmunoTech Gross Profit Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech Business Description

Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

AIM ImmunoTech Headlines

No Headlines